Apg Asset Management N.v. buys $357,562,267 stake in Amgen (AMGN)

Amgen (AMGN) : Apg Asset Management N.v. scooped up 68,900 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 2,066,595 shares of Amgen which is valued at $357,562,267.Amgen makes up approximately 0.66% of Apg Asset Management N.v.’s portfolio.

Other Hedge Funds, Including , Baird Financial Group reduced its stake in AMGN by selling 15,912 shares or 10.76% in the most recent quarter. The Hedge Fund company now holds 132,006 shares of AMGN which is valued at $22,839,678. Amgen makes up approx 0.20% of Baird Financial Group’s portfolio.Capital Advantage reduced its stake in AMGN by selling 379 shares or 16.78% in the most recent quarter. The Hedge Fund company now holds 1,880 shares of AMGN which is valued at $325,278. Amgen makes up approx 0.09% of Capital Advantage’s portfolio.Trust Co Of Virginia Va boosted its stake in AMGN in the latest quarter, The investment management firm added 46,843 additional shares and now holds a total of 52,183 shares of Amgen which is valued at $8,502,176. Amgen makes up approx 1.44% of Trust Co Of Virginia Va’s portfolio.

Amgen opened for trading at $174.44 and hit $175.99 on the upside on Tuesday, eventually ending the session at $174.4, with a gain of 0.03% or 0.05 points. The heightened volatility saw the trading volume jump to 23,76,437 shares. Company has a market cap of $130,514 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *